The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Long‐term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi‐site trial
Open accessAbstract
Aims: To compare long‐term outcomes among participants randomized to buprenorphine or methadone. Design, Setting and Participants: Follow‐up was conducted in 2011–14 of 1080 opioid‐dependent participants entering seven opioid treatment programs in the United States between 2006 and 2009 and randomized (within each program) to receive open‐label buprenorphine/naloxone or methadone for up to 24 weeks; 795 participants completed in‐person interviews (~74% follow‐up interview rate) covering on average 4.5 years. Measurements: Outcomes were indicated by mortality and opioid use. Covariates included demographics, site, cocaine use and treatment experiences. Findings: Mortality was not different between the two randomized conditions, with 23 (3.6%) of 630 participants randomized to buprenorphine having died versus 26 (5.8%) of 450 participants randomized to methadone. Opioid use at follow‐up was higher among participants randomized to buprenorphine relative to methadone [42.8 versus 31.7% positive opioid urine specimens, P < 0.01, effect size (h) = 0.23 (0.09, 0.38); 5.8 days versus 4.4 days of past 30‐day heroin use, P < 0.05, effect size (d) = 0.14 (0.00, 0.28)]. Opioid use during the follow‐up period by randomization condition was also significant (F(7,39 600) = 3.16; P < 0.001) due mainly to less treatment participation among participants randomized to buprenorphine than methadone. Less opioid use was associated with both buprenorphine and methadone treatment (relative to no treatment); no difference was found between the two treatments. Individuals who are white or used cocaine at baseline responded better to methadone than to buprenorphine. Conclusions: There are few differences in long‐term outcomes between buprenorphine and methadone treatment for opioid dependence, and treatment with each medication is associated with a strong reduction in opioid use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Maintenance Medication for Opiate Addiction: The Foundation of Recovery
Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461
Discontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes
Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.12.011 · Cited by 176
Cited by
Comparative effectiveness of different treatment pathways for opioid use disorder.
Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.20622 · Cited by 995
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Self-citationStrang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
Medication Treatment of Opioid Use Disorder
Bell, J., & Strang, J. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.06.020 · Cited by 328
Goedel, W. C., Shapiro, A., Cerdá, M., Tsai, J. W., Hadland, S. E., & Marshall, B. D. L. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.3711 · Cited by 295
Lofwall, M. R., Walsh, S. L., Nunes, E. V., Bailey, G. L., Sigmon, S. C., Kampman, K. M., Frost, M., Tiberg, F., Linden, M., Sheldon, B., et al. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.1052 · Cited by 255
The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review
Carroll, K. M., & Weiss, R. D. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16070792 · Cited by 211
Self-citationRelapse to opioid use disorder after inpatient treatment: protective effect of injection naltrexone
Nunes, E. V., Gordon, M., Friedmann, P. D., Fishman, M. J., Lee, J. D., Chen, D. T., Hu, M. C., Boney, T. Y., Wilson, D., & O'Brien, C. P. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.04.016 · Cited by 122
Methadone and Suboxone® mentions on Twitter: Thematic and Sentiment Analysis (Preprint)
Chenworth, M., Perrone, J., Hogg, W., & Sarker, A. (2020) · doi:10.2196/preprints.19700
Metadata
- Authors
- Hser, Y., Evans, E., Huang, D., Weiss, R., Saxon, A., Carroll, K. M., Woody, G., Liu, D., Wakim, P., Matthews, A. G., Hatch‐Maillette, M., Jelstrom, E., Wiest, K., McLaughlin, P., & Ling, W.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2016-01-13
- Volume
- 111
- Issue
- 4
- Pages
- 695-705
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2173844711
- Cited by
- 221
- References
- 3
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.